Ultrasound-guided transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a new minimally invasive interventional therapy

Abstract

Background

Although there are different treatments for benign prostate hyperplasia, their efficacy and safety differ. We are currently exploring a new minimally invasive interventional therapy for benign prostatic hyperplasia (BPH).

Purpose

To determine the feasibility, effectiveness, and safety of ultrasound-guided transperineal laser ablation (US-TPLA) for the treatment of BPH.

Material and Methods

Twenty patients with BPH (mean age = 73.9 ± 9.2 years) who underwent US-TPLA from June 2018 to January 2020 with a subsequent six-month follow-up were retrospectively reviewed. After local anesthesia, a 21-G trocar was inserted into the prostate tissue under ultrasound monitoring, followed by 1064 nm diode laser irradiation. Changes in international prostate symptom score (IPSS), quality of life (QoL), maximum urinary flow rate (Qmax), postvoid residual (PVR), prostate volume, and complications were evaluated six months after surgery.

Results

All patients underwent the operation successfully without serious complications. After six months, the average IPSS improved from 22.7 ± 5.3 to 9.1 ± 3.2 (P < 0.001), the QoL improved from 4.9 ± 1.7 to 2.3 ± 1.3 (P < 0.001), the Qmax improved from 8.5 ± 3.0 to 15.2 ± 4.8 mL/s (P < 0.001), the PVR increased from 78.7 ± 58.8 to 30.3 ± 34.2 (P < 0.05), and the mean prostate volume ranged from 70.8 ± 23.8 to 54.7 ± 20.9 mL (P < 0.05).

Conclusion

US-TPLA is safe and feasible for the treatment of BPH. An evaluation at the six-month follow-up is effective.

Keywords

Ultrasonography transperineal laser ablation minimally invasive treatments benign prostatic hyperplasia

Get full access to this article

View all access options for this article.

References

Parsons

JK.

Benign prostatic hyperplasia and male lower urinary tract symptoms: Epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010; 5:212–218.

Roehrborn

CG.

Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: Achievements and limitations. Rev Urol 2008; 10:14–25.

Foster

Dahm

Kohler

, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol 2019; 202:592–598.

Martinez

Rodríguez

Rojas

, et al. Fetal laser ablation of feeding artery of cystic lung lesions with systemic arterial blood supply. Ultrasound Obstet Gynecol 2017; 49:744–750.

Negro

Greco

Deandrea

, et al. Twelve-month volume reduction ratio predicts regrowth and time to regrowth in thyroid nodules submitted to laser ablation: A 5-year follow-up retrospective study. Korean J Radiol 2020; 21:764–772.

Jiang

Tian

Bao

, et al. EUS dating with laser ablation against the caudate lobe or left liver tumors: A win-win proposition? Cancer Biol Ther 2018; 19:145–152.

Hall

Gonzalez

Fried

NM.

Thulium fiber laser ablation of kidney stones using an automated, vibrating fiber. J Biomed Opt 2019; 24:1–10.

Patelli

Ranieri

Paganelli

, et al. Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: A feasibility study. Cardiovasc Intervent Radiol 2017; 40:1440–1446.

Kollenburg

RAAV

Riel

LAMJGV

Bloemen

, et al. Transperineal laser ablation treatment for lower urinary tract symptoms due to benign prostatic obstruction: Protocol for a prospective in vivo pilot study. JMIR Res Protoc 2020; 9:e15687.

10.

Chughtai

Forde

Thomas

DDM

, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers 2016; 2:16031.

11.

Roehrborn

Egan

Miner

, et al. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment. BJU Int 2016; 118:153–160.

12.

Woodard

Manigault

McBurrows

, et al. Management of benign prostatic hyperplasia in older adults. Consultant Pharm 2016; 31:412–424.

13.

Cellek

Cameron

Cotter

, et al. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nat Rev Urol 2014; 11:231–241.

14.

Kim

Alawamlh

OAH

Chughtai

, et al. Lower urinary tract symptoms following transurethral resection of prostate. Curr Urol Rep 2018; 19:85.

15.

Sun

Shu

, et al. The diagnostic value of prostate cancer between holmium laser enucleation of the prostate and transurethral resection of the prostate for benign prostatic hyperplasia: A retrospective comparative study. Int J Surg 2020; 79:217–221.

16.

Otero

Gómez

González

, et al. Critical analysis of a multicentric experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia: Outcomes and complications of 10 years of routine clinical practice. BJU Int 2020; 126:177–182.

17.

Spaliviero

Araki

Page

, et al. Catheter-free 120W lithium triborate (LBO) laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH). Lasers Surg Med 2008; 40:529–534.

18.

Whitty

Crosland

Hewson K , et al. A cost-minimisation analysis comparing photoselective vaporisation (PVP) and transurethral resection of the prostate (TURP) for the management of symptomatic benign prostatic hyperplasia (BPH) in Queensland, Australia. BJU Int 2014; 2:21–28.

19.

Becker

Orywal

Gross

, et al. Thulium vapoenucleation of the prostate (ThuVEP) for prostates larger than 85 ml: long-term durability of the procedure. Lasers Med Sci 2019; 34:1637–1643.

20.

Castellani

Cindolo

Nunzio

, et al. Comparison between thulium laser vapoenucleation and greenlight laser photoselective vaporization of the prostate in real-life setting: Propensity score analysis. Urology 2018; 121:147–152.

21.

Picel

Hsieh

Shapiro

, et al. Prostatic artery embolization for benign prostatic hyperplasia: Patient evaluation, anatomy, and technique for successful treatment. Radiographics 2019; 39:1526–1548.

22.

Huang

, et al. An updated meta-analysis of prostatic arterial embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. World J Urol 2019; 38:2455–2468.

23.

Pacella

Patelli

Lapicca

, et al. Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: A feasibility study. Results at 6 and 12 months from a retrospective multi-centric study. Prostate Cancer Prostatic Dis 2020; 23:356–363.

24.

Rienzo

Lorusso

Minafra

, et al. Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction. Eur Urol 2020. DOI: 10.1016/j.eururo.2020.08.018.